Heroin-assisted treatment (HAT) in Norway, a specialized medical intervention for severe opioid addiction, has demonstrated significant improvements in patient health and quality of life over a four-year pilot period, according to an evaluation by the Norwegian Center for Addiction Research (SERAF). While effective for a highly vulnerable, treatment-resistant population, researchers note the program is costly and recommend maintaining current local services rather than pursuing national expansion.
How Heroin-Assisted Treatment Works in Norway
Heroin-assisted treatment (HAT) functions as a structured, interdisciplinary medical intervention rather than a standalone medication. At clinics in Oslo and Bergen, patients with severe heroin addiction receive pharmaceutical heroin twice daily under the direct supervision of health personnel.
According to Desiree Eide, a researcher at SERAF, this approach targets individuals for whom standard opioid agonist treatment (OAT)—such as methadone or buprenorphine—has not been effective. The treatment framework extends beyond the medication itself, incorporating intensive medical follow-up, psychological support, and assistance with social challenges like housing and financial stability.
Patient Outcomes and Health Improvements
The four-year evaluation found that HAT provides a measurable, gradual improvement in the physical and mental health of its participants. While the study size was too limited to calculate direct mortality reductions, Professor Thomas Clausen of SERAF notes that patients who stabilize in the program experience a lower risk of fatal overdoses, largely due to a decrease in the use of narcotics.
Data from the evaluation indicates:
- Patients report reduced criminal activity over time.
- There is a measurable decline in the use of illegal heroin.
- A majority of participants experience improved overall quality of life.
“Some say their life has been turned around, they have begun working, and describe their everyday life as completely changed,” says Clausen. “Others report more subtle changes, but still experience improvements after being in HAT.”
Is HAT a Permanent Solution for Addiction?
The evaluation suggests that HAT often serves as a transitional bridge rather than a lifelong treatment. Data shows that 88% of patients who were discharged as planned transitioned into ordinary OAT programs. This indicates that the intensive supervision provided by HAT can stabilize patients, allowing them to eventually move toward less intensive, standard forms of addiction care.
Why National Expansion is Not Recommended
Despite the positive clinical outcomes, the evaluation concludes that the model is not suitable for national implementation due to its high cost and resource requirements.
“Based on the evaluation, we do not recommend that the offer be expanded nationally. We consider it too expensive,” says Clausen.
Researchers emphasize that the future of the program remains a political decision. The current recommendation is to maintain existing clinics in Oslo and Bergen, where they remain accessible to the population segment most in need of this intensive level of care. Future developments will depend on how the service is integrated with other healthcare offerings and how it is prioritized within the broader context of Norwegian addiction treatment policy.
Worth a look